| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Division of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan, Italy
The RET proto-oncogene encodes a receptor tyrosine kinase
for transforming growth factor-ß-related neurotrophic factors, which
include GDNF and neurturin. The expression of RET
proto-oncogene was detected in several tissues, such as spleen, thymus,
lymph nodes, salivary gland, and spinal cord, and in several neural
crest-derived cell lines. RET expression in the thyroid
gland was reported to be restricted to neural crest-derived C cells.
The presence of RET mRNA or protein has not yet been
reported in thyroid follicular cells. We previously demonstrated the
expression of oncogenic rearranged versions of RET in
papillary thyroid carcinomas: tumors derived from thyroid follicular
cells. To assess the expression of the normal RET
proto-oncogene in follicular cells, we analyzed its expression in a
panel of neoplasias originating from thyroid follicular epithelial
cells: papillary carcinomas and both follicular adenomas and
carcinomas. We also demonstrated the presence of RET
normal transcripts in two follicular thyroid carcinoma lymph node
metastases. Moreover, we found the presence of the
RET/ELE1 transcript, the reciprocal
complementary form of the oncogenic fusion transcript
ELE1/RET, in a papillary thyroid
carcinoma specimen expressing the
RET/PTC3 oncogene, thus demonstrating
that the RET promoter is active in those cells after
rearrangement. Finally, we show that in a papillary carcinoma-derived
cell line expressing the proto-RET receptor and the related GFR
2
co-receptor, GDNF treatment induced RET tyrosine phosphorylation and
subsequent signal transduction pathway, indicating that RET could be
active in thyroid follicular cells.
This article has been cited by other articles:
|
|
 |
|
  M. Santoro, R. M. Melillo, and A. Fusco RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur. J. Endocrinol., November 1, 2006; 155(5): 645 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Xing BRAF mutation in thyroid cancer Endocr. Relat. Cancer, June 1, 2005; 12(2): 245 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Melillo, A. M. Cirafici, V. De Falco, M. Bellantoni, G. Chiappetta, A. Fusco, F. Carlomagno, A. Picascia, D. Tramontano, G. Tallini, et al. The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma Am. J. Pathol., August 1, 2004; 165(2): 511 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sadetzki, R. Calderon-Margalit, B. Modan, S. Srivastava, and R. M. Tuttle Ret/PTC Activation in Benign and Malignant Thyroid Tumors Arising in a Population Exposed to Low-Dose External-Beam Irradiation in Childhood J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2281 - 2289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yano, N. Uematsu, T. Yashiro, H. Hara, E. Ueno, M. Miwa, G. Tsujimoto, Y. Aiyoshi, and K. Uchida Gene Expression Profiling Identifies Platelet-Derived Growth Factor as a Diagnostic Molecular Marker for Papillary Thyroid Carcinoma Clin. Cancer Res., March 15, 2004; 10(6): 2035 - 2043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Collins, G. Chiappetta, A. B. Schneider, M. Santoro, F. Pentimalli, L. Fogelfeld, T. Gierlowski, E. Shore-Freedman, G. Jaffe, and A. Fusco RET Expression in Papillary Thyroid Cancer from Patients Irradiated in Childhood for Benign Conditions J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3941 - 3946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Kroll Molecular Rearrangements and Morphology in Thyroid Cancer Am. J. Pathol., June 1, 2002; 160(6): 1941 - 1944. [Full Text] [PDF]
|
|
|
|
|
|
A. Fusco, G. Chiappetta, P. Hui, G. Garcia-Rostan, L. Golden, B. K. Kinder, D. A. Dillon, A. Giuliano, A. M. Cirafici, M. Santoro, et al. Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma : A Search for the Early Precursors of Papillary Cancer Am. J. Pathol., June 1, 2002; 160(6): 2157 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chiappetta, P. Toti, F. Cetta, A. Giuliano, F. Pentimalli, I. Amendola, S. Lazzi, M. Monaco, L. Mazzuchelli, P. Tosi, et al. The RET/PTC Oncogene Is Frequently Activated in Oncocytic Thyroid Tumors (Hurthle Cell Adenomas and Carcinomas), but Not in Oncocytic Hyperplastic Lesions J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 364 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Santoro, M. Papotti, G. Chiappetta, G. Garcia-Rostan, M. Volante, C. Johnson, R. L. Camp, F. Pentimalli, C. Monaco, A. Herrero, et al. RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 370 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Nikiforova, C. M. Caudill, P. Biddinger, and Y. E. Nikiforov Prevalence of RET/PTC Rearrangements in Hashimoto's Thyroiditis and Papillary Thyroid Carcinomas International Journal of Surgical Pathology, January 1, 2002; 10(1): 15 - 22. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
